Uncategorized
EV06 ophthalmic solution for presbyopia improves visual outcomes in phase 1/2 study
Presbyopic patients who were treated with EV06 ophthalmic solution showed an improvement in visual outcomes in a phase 1/2 study, Encore Vision announced in a press release. “This clinical trial was designed to confirm or not confirm that topically applied lipoic acid at a concentration of 1.5% could increase the elasticity of the human lens and enhance accommodation,” OSN Chief Medical Editor Richard L. Lindstrom, MD, told Ocular Surgery News.